New data independently confirms and extends laboratory findings and expands safety profile of ATH434
new clinical and experimental pharmacology data for its lead drug candidate ATH434 (formerly PBT434) has been selected for presentation at the 2020 International Congress of Parkinson's Disease and Movement Disorders (MDS 2020) and the American Neurological Association's 2020 Annual Meeting (ANA 2020).
both conferences will be held in a virtual format with MDS 2020 being held 12-16th September, and ANA 2020 to be held 4-9th October.
finance.yahoo.com/news/data-independently-confirms-extends-laboratory-013300738.html?guce_referrer=aHR0cHM6Ly9maW52aXouY29tL3F1b3RlLmFzaHg_dD1BVEhFJnR5PWMmcD1kJmI9MQ&guce_referrer_sig=AQAAAFv8Qyp4w5sxLSlYXQcvxwHtDYiC6BjQv6ftwx12gUlncWhzSXL2amnp918lsgtlRB2txuAcdRxCD6Rha3UQPZ-sp2F22IolvI9ZM-IiY_Co0QQ4gD5QpZZvsXv1v3FAI86NStkyjKN6iKm-g50bUdexjgkfOnDdjod7rxM2XopL&_guc_consent_skip=1596622595
new clinical and experimental pharmacology data for its lead drug candidate ATH434 (formerly PBT434) has been selected for presentation at the 2020 International Congress of Parkinson's Disease and Movement Disorders (MDS 2020) and the American Neurological Association's 2020 Annual Meeting (ANA 2020).
both conferences will be held in a virtual format with MDS 2020 being held 12-16th September, and ANA 2020 to be held 4-9th October.
finance.yahoo.com/news/data-independently-confirms-extends-laboratory-013300738.html?guce_referrer=aHR0cHM6Ly9maW52aXouY29tL3F1b3RlLmFzaHg_dD1BVEhFJnR5PWMmcD1kJmI9MQ&guce_referrer_sig=AQAAAFv8Qyp4w5sxLSlYXQcvxwHtDYiC6BjQv6ftwx12gUlncWhzSXL2amnp918lsgtlRB2txuAcdRxCD6Rha3UQPZ-sp2F22IolvI9ZM-IiY_Co0QQ4gD5QpZZvsXv1v3FAI86NStkyjKN6iKm-g50bUdexjgkfOnDdjod7rxM2XopL&_guc_consent_skip=1596622595
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。